Trevena (TRVN) Files $86.25M IPO
Tweet
Share
E-mail
Get Alerts TRVN Hot Sheet
Join SI Premium – FREE
Trevena, Inc. (Nasdaq: TRVN) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. The company plans to list on the Nasdaq Global Market under the ticker,
The offering is being made via Barclays, Jefferies, Canaccord Genuity, JMP Securities, and Needham & Company.
Trevena a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.
TRVN.
The offering is being made via Barclays, Jefferies, Canaccord Genuity, JMP Securities, and Needham & Company.
Trevena a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs.
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
Jefferies & Co, Needham & Company, JMP Securities, Barclays, Canaccord Genuity, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
